Omega Therapeutics (Omega Therapeutics) Quick Ratio : 2.87 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Omega Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Omega Therapeutics's quick ratio for the quarter that ended in Mar. 2024 was 2.87.

Omega Therapeutics has a quick ratio of 2.87. It generally indicates good short-term financial strength.

The historical rank and industry rank for Omega Therapeutics's Quick Ratio or its related term are showing as below:

OMGA' s Quick Ratio Range Over the Past 10 Years
Min: 1.19 Med: 8.22 Max: 19.13
Current: 2.87

During the past 5 years, Omega Therapeutics's highest Quick Ratio was 19.13. The lowest was 1.19. And the median was 8.22.

OMGA's Quick Ratio is ranked worse than
56.01% of 1555 companies
in the Biotechnology industry
Industry Median: 3.49 vs OMGA: 2.87

Omega Therapeutics Quick Ratio Historical Data

The historical data trend for Omega Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omega Therapeutics Quick Ratio Chart

Omega Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Quick Ratio

1.19

3.12

19.13

6.26

3.35

Omega Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Quick Ratio	Get a 7-Day Free Trial													8.22	3.71	3.80	3.35	2.87

Competitive Comparison of Omega Therapeutics's Quick Ratio

For the Biotechnology subindustry, Omega Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omega Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omega Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Omega Therapeutics's Quick Ratio falls into.

Omega Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Omega Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(89.884	-	0)	/	26.806
	=	3.35

Omega Therapeutics's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(70.89	-	0)	/	24.68
	=	2.87

Omega Therapeutics (NAS:OMGA) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Omega Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Omega Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Omega Therapeutics (Omega Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omega Therapeutics Inc (NAS:OMGA) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.omegatherapeutics.com

Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. It primarily operates in the U.S.

Executives

Michelle C Werner	director	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Christian S Schade	director	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Richard A Young	director, 10 percent owner	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Flagship Pioneering Special Opportunities Fund Ii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Rainer J. Boehm	director	C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
Joshua Reed	officer: Chief Financial Officer	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Kevin Mcmanus	officer: Chief Human Resources Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Ling Zeng	officer: See Remarks	C/O DICERNA PHARMACEUTICALS, INC., 33 HAYDEN AVENUE, LEXINGTON MA 02421
Yan Moore	officer: Chief Medical Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
David A Berry	director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Roger Sawhney	officer: Chief Financial Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Flagship Pioneering Fund Vi General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142